31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

December 19, 2019

Primary Completion Date

June 7, 2021

Study Completion Date

June 7, 2021

Conditions
Parkinson's Disease
Interventions
DRUG

Gold Nanocrystals

CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.

Trial Locations (1)

75390

UT Southwestern, Dallas

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

University of Texas Southwestern Medical Center

OTHER

lead

Clene Nanomedicine

INDUSTRY

NCT03815916 - 31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Parkinson's Disease | Biotech Hunter | Biotech Hunter